Navigation Links
Once Monthly Dosing: How Much of a Competitive Advantage is it? Rheumatologists Provide Insight in the Baseline Report of LaunchTrends(TM): SIMPONI(TM)
Date:6/4/2009

fielded on June 22 and will be expanded to include CIMZIA in the competitive set. The results will be published in mid-July.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. To purchase this report or to learn more about BioTrends' syndicated publications, please contact Paul Callahan at (610) 363-3872 or visit us at www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Nuvilex, Inc. Announces Monthly Investor Conference Call
2. SIMPONI(TM) (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
3. National Council on Disability Monthly Bulletin for February, 2009
4. U.S. Labor Department to begin new monthly data series on people with disabilities from Current Population Survey on Feb. 6
5. Medical City Hospital Named by Texas Monthly as One of the Top Ten Best Companies to Work for in Texas
6. National Council on Disability Monthly Bulletin for November 2008
7. Renowned Thoracic Surgeon Recognized as Top Doctor by Peers in Annual New Jersey Monthly Magazine Survey
8. National Council on Disability Monthly Bulletin for October 2008
9. National Council on Disability Monthly Bulletin for June, 2008
10. National Council on Disability Monthly Bulletin for March 2008
11. National Council on Disability Monthly Bulletin for February, 2008

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...nn.,Nov.25/PRNewswire-USNewswire/--Whenmostpeopleh...practorcanalsogivepatientsthehelptheyneed.TMJstand...w(mandible)contacts/connectswithyourskull(temporal...Jdysfunctionarepainwithchewing,clickingorpoppingof...nctionincluding:headaches,fatigue,sleepdisturbance...
(Date:11/25/2009)...Nov.25/PRNewswire/-SentinelleMedicalInc.,aleadingm...nsoftwarelaunchesasuiteofnewleadingedgeclinicalapp...ormatthisyear,sRadiologicalSocietyofNorthAmerica(R...5800,HallA).Theapplicationsleveragetheuniquehighqu...agingcoilsandsupportmultipleimagingmodalitiesformu...
(Date:11/25/2009)...ISCO,Nov.25/PRNewswire/--TheBayAreaAirQualityManag...pare the Air Alert forThursday,November...anyothersolidfuel,bothindoorsandoutdoors. ,, "C...ytomorrow,"saidJackBroadbent,executiveofficerofthe...hehealthoftheirneighborsandfellowcommunitymemberst...
(Date:11/25/2009)... discovery that grew out of a collaboration betwee...offer hope to the nearly 10 million Americans who ...lso known as hardening of the arteries, peripheral... problem in which narrowed arteries reduce blood f...d flag for vascular disease, heart attack and stro...
(Date:11/25/2009)... Evaluation and treatment clinics to resu...stock (Vocus) November 25, 2009 -- Centegra Health... and H1N1 vaccine shots at four Centegra Primary C...nt of vaccine has arrived. The clinics are at CPC ...nry and will be open as follows: ,   F...
Breaking Medicine News(10 mins):Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4
...TIN, Texas, May 22 Whole Foods Market,(Nasdaq: W...ds supermarket,announced today it has launched "De...s America, whether it be at backyard barbecues, fa...kes to win,Weber(R) Grills and a VIP concert trip ...
...MADISON - In our brains, where millions of signals...a relay race, all the critical baton passes take p...ell endings have to be just the right size for mes...ties, and other neurological disorders. , In a f...
...puter-based test delivery provides greater conveni... certification, WASHINGTON, May 22 The Pharmacy ...day that over 300,000 pharmacy,technicians have of...ion or transfer process since the program,s incept...
...line in function needs to be addressed more aggres...ealthDay News) -- Children with sickle cell diseas... as they age, compared with other children of the ...n obstructive or asthma-like pattern. , "The rest...
...CHICAGO (May 22, 2008) - As people begin to realiz...life, many are turning to alternative methods to p...y economically feasible to wear while waiting for ... issue of General Dentistry, the Academy of Genera...
...TA MONICA, Calif., May 22 The California,Senate r... firm that was,forced to change its name after pri...w., The bill, SB 1096 (Calderon), which was grant...medical information --,including a patient,s illne...
Other Medicine News:Health News:Whole Foods Market's(R) 'Destination Summer' Celebrates a Journey of American Flavors; Kicks Off With Sweepstakes & Free Shopper Grilling Guide 2Health News:Whole Foods Market's(R) 'Destination Summer' Celebrates a Journey of American Flavors; Kicks Off With Sweepstakes & Free Shopper Grilling Guide 3Health News:Whole Foods Market's(R) 'Destination Summer' Celebrates a Journey of American Flavors; Kicks Off With Sweepstakes & Free Shopper Grilling Guide 4Health News:At the synapse: Gene may shed light on neurological disorders 2Health News:At the synapse: Gene may shed light on neurological disorders 3Health News:Pharmacy Technician Certification Board (PTCB) Announces Milestone: 300,000 Certified Pharmacy Technicians (CPhT) 2Health News:Pharmacy Technician Certification Board (PTCB) Announces Milestone: 300,000 Certified Pharmacy Technicians (CPhT) 3Health News:Lung Trouble Associated With Sickle Cell in Kids 2Health News:Temporary dentures improve patients' smiles and overall health 2Health News:Sponsor of Drug Bill Rejected by CA Senate Today Changed Its Name After Privacy Violations 2Health News:Sponsor of Drug Bill Rejected by CA Senate Today Changed Its Name After Privacy Violations 3
(Date:11/25/2009)...AccordingtoMillenniumResearchGroup(MRG),theglobala...early$3billionUSmarketfortraumafixationdeviceswill...etherecenteconomicslowdown.MRG,s USMarketsforTraum...highlydynamicoverthenextfiveyears,withcompetitorsi...dsegmentsofthetraumafixationmarket,fuelingmarketgr...
(Date:11/25/2009)...linker.comannouncesthatanewmarketresearchreportisa...ery-USMarketTrends&Analysis http://www.report...Market-Trends--Analysis.html ,, TheUSintranasa...euticapplicationsfromthedeliveryofconventionalloca...cdrugs.Thefutureofthetechnologyhingesontotheeffect...
(Date:11/24/2009)...a/--ChindexInternational,Inc.,("Chindex")(Nasdaq: ...n,healthcareproductsandservicesinthePeople,sRepubl...he21stAnnualPiperJaffray,"Unplugged"HealthCareConf...eHotel. , Managementiscurrentlyscheduledtopre...e-on-onemeetingsthroughouttheday.Awebcast,ofthepre...
Breaking Medicine Technology:US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5Chindex International to Present at Piper Jaffray Health Care Conference 2EF Johnson Technologies Inc Highlights New Products at APCO 2009 54570 1EF Johnson Technologies Inc Highlights New Products at APCO 2009 54570 2EF Johnson Technologies Inc Highlights New Products at APCO 2009 54570 3Statewide program to improve emergency care for children 54567 1Statewide program to improve emergency care for children 54567 2Scientists take early steps toward mapping epigenetic variability 9583 1Scientists take early steps toward mapping epigenetic variability 9583 2
...udy to Show That Extended,Thromboprophylaxis Reduc... Statistically Significant 44% , PARIS, July 8, 20...ed today the results of the EXCLAIM (EXtended CLin...study, which showed,the benefit of extended prophy... mobility by demonstrating the superiority of 5 we...
...Inc. (NASDAQ:INSM), a ,biopharmaceutical company f...r the treatment of metabolic diseases with unmet,...nt at this,week,s C.E. Unterberg, Towbin (CEUT) Em... City. , The conference, to be held at the Mand...om Tuesday, July 10th through Thursday,July 12th....
Other Medicine Technology:New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 2New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 3New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 4New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 5New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 6Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference 2
P-1069-A-SS
P-1068-A-SS
P-1066-SS
..., solid cast aluminum frame, armrest, footrest, an...tion full range articulating headrest, securely lo...red cushions with anti-viral upholstery, self-lubr...colors. Optional features: foot pedal control, sin...
Medicine Products: